Brief: Neoimmunetech Receives U.S. FDA Ind Clearance For Phase 1 Study Of NT-I7 For Treatment Of Kaposi Sarcoma In Patients With Or Without HIV Infection
26/07/2021 12:12
July 26 (Reuters) - Neoimmunetech Inc 950220.KQ :
* NEOIMMUNETECH RECEIVES U.S. FDA IND CLEARANCE FOR PHASE 1
STUDY
OF NT-I7 (EFINEPTAKIN ALFA) FOR TREATMENT OF KAPOSI SARCOMA IN
PATIENTS WITH OR WITHOUT HIV INFECTION
Source text for Eikon: ID:nBw66rYm0a
Further company coverage: 950220.KQ
Recent news on Neoimmunetech
See all newsBrief: Emmaus Life Sciences Enters License And Distribution Agreement With Neoimmunetech
Brief: Neoimmunetech To Conduct Capital Increase Of 65 Billion Won For Operational Funds
Brief: FDA Grants Orphan Drug Designation Status To NeoImmuneTech's NT-I7 For Advanced Pancreatic Cancer Treatment
Brief: FDA Grants Orphan Drug Tag to NeoImmuneTech's Acute Radiation Syndrome Treatment
Brief: Neoimmunetech Presents Phase 1 Study Data At Society For Neuro-Oncology Annual Meeting